Nursing Review November-December 2015 | Page 21

clinical practice Seeds of a cure Research examining Australian plants as treatments for golden staph, wounds and more gains funding boost. By Dallas Bastian A ustralian plants may soon help healthcare professionals combat golden staph infections, heal wounds, and even treat diseases such as Alzheimer’s and Parkinson’s. Queensland University of Technology research into the use of plants in treating these conditions has been bolstered by $1 million in funding from an Australian biotech company and the Commonwealth Government. The commercial research agreement and two Commonwealth Research Connection grants with Health Focus Products Australia (HFPA) will provide $1,035,614 in funding over three years to support three areas of research. Dr Trudi Collet, from the Indigenous Medicines Group in the Queensland University of Technology Institute of Health and Biomedical Innovation, says the research will draw upon Australia’s varied flora. “Australia’s biodiversity is unique and its application for the treatment of global infections and diseases has incredible potential,” Collet says. She says native plants have a rich history with Indigenous people and have been used for a variety of conditions, including wounds. “Irrespective of where traditional accounts with regards to the use of medicinal plants have come from, a lot of that knowledge [hasn’t] been scientifically validated for various uses. That’s where my research comes in,” she says. One of the projects will explore the use of three different plants in the treatment of chronic wounds. The research will involve isolating the bioactive compounds from the plants and determining whether they can enhance cellular proliferation, increasing the speed of wound healing. “Globally, more than 7 million people suffer from a chronic wound, while in Australia, 433,000 people are diagnosed each year,” Collet says. “The associated treatment costs are estimated to be in excess of $2.6 billion.” Another project will look into using a plant to treat golden staph. Similarly, the researchers will isolate and identify bioactive compounds. “We have some preliminary data with regards to this particular plant, and it is shown to have exceptional antimicrobial activity against golden staph,” Collet explains. “The whole premise of this particular project is to go ahead and identify the bioactive compound or compounds that have this effect against the bacteria.” She says this could help people with golden staph infections and chronic wounds and the professionals who treat them. “As we know, there’s an increase in antibiotic resistance,” she says. “There is also high incidence of golden staph infections acquired in hospitals and the community. [Having a novel antibiotic that can] successfully treat and clear a golden staph infection will have an enormous impact, not just within Australia, but on a global scale as well.” She adds that the professionals who treat people with chronic wounds and golden staph infections will also benefit by seeing the increased speed of healing. “The cost associated with managing and treating a chronic wound are also going to be decreased,” she says. Finally, the research will also look into the treatment of Alzheimer’s disease and Parkinson’s disease. Collet says this project will focus on whether particular bioactive compounds can reduce the progression of Alzheimer’s and possibly reverse its effects. She explains that because people with Parkinson’s often have dementia as well, there is also potential for a crossover treatment. Dr Mark Baldock, HFPA chairman and founder, says the funding recognises the research’s value, even at its earliest stages. “With our ageing population, we are going to see an increase in health problems like dementia and chronic wounds, while the rise in antibiotic-resistant infections is another concern,” Baldock says. “I was very excited to hear of this work by Dr Collet. We have a common goal.” He says he is hopeful that other biotech companies will look at offering the same kind of early-entry research funding. ■ nursingreview.com.au | 21